English
banner
Products
Home

Prostaglandin Series

TRAVOPROST 157283-68-6

TRAVOPROST 157283-68-6

99% up, USP32
  • Product Details

Product Information


Product name

Travoprost

Molecular Formula

C26H35F3O6

Molecular Weight

500.55

CAS No.

157283-68-6

Quality Standard

96% up, USP32

Appearance

Colorless oil


COA of Travoporst


Tests

Specifications

Results

Description

A pale yellow to colorless oil

A colorless oil

Identification

TLC; HPLC

Complies

Specific Rotation

+52°~+58°

+53.15°

Water

1.0%

0.30%

Related compunds

Epoxide derivative 1)0.4%

Not detectable

15-epi Diastereomer 2)0.1%

0.03%

5,6-trans Isomer 3)3.5%

0.26%

15-Keto derivative 4)0.3%

0.06%

Any other impurity 0.1%

0.03%

Total other impurities 1.0%

0.06%

Residue Solvent

Isopropanol0.5%

Not detectable

Ethyl acetate0.25%

Not detectable

N-Hexane 0.029%

Not detectable

Ethanol0.5%

0.33%

Purity by HPLC

96.0%~102%

99.59%


Usage


Function of Travoprost
Glaucoma is a serious eye disease that threatens human health. It is a blinding eye disease that seriously threatens human visual function. It is the second most blind factor in the world. Its main features are increased intraocular pressure, optic nerve damage, decreased vision and visual field. Shrinkage, severe cases and even vision loss. At present, there is no direct treatment for glaucoma optic neuropathy. The main treatment is to control intraocular pressure and prevent further damage to the optic nerve function. Glaucoma local ocular pressure-lowering drugs have been focusing on the study of inhibiting the production of ciliary body aqueous humor and promoting the outflow of trabecular meshwork water. The drugs for treating glaucoma are mainly eye drops, including β-blockers and pseudo-sympathetic drugs. , Carbonic anhydrase inhibitors, α-receptor agonists, and prostaglandin (PG) analogs. PGs are a class of unsaturated 20-carbon Chemicalbook fatty acids derived from arachidonic acid. PGs, especially PGF2α, are currently considered to be the most promising and effective ocular local pressure reducing drugs. PG analogues such as PGF2α reduce the intraocular pressure by activating PGFP receptors. The combination of these drugs and the PGFP receptor initiates a series of biochemical reactions, opening the uveal sclera drainage pathway, increasing the outflow of aqueous humor, and thereby reducing intraocular pressure. PG analogs, especially PGFP receptor agonists, are a class of approved and effective new drugs for lowering intraocular pressure. Due to the good effect of lowering intraocular pressure, fewer adverse reactions, and fewer times of medication, they have become the main clinical eye drop Press drugs.

Travoprost is a new type of PG drugs, is an analogue of PGF2α, has a high selectivity and affinity for PGFP receptors, is a complete agonist, is by the US Food and Drug Administration (FDA) A PG drug approved in September 2006 for the treatment of primary open-angle glaucoma and ocular hypertension. The molecular structure of travoprost contains a pentene ring with α- and ω-carbon chains. The esters at the end of the α-chain help penetrate the cornea and decompose into free acids in the stroma of the cornea. FP receptors combine to reduce intraocular pressure by increasing the outflow of aqueous humor through the uveal scleral pathway.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

BIMATOPROST
BIMATOPROST 155206-00-1
99.5% up by HPLC
ALPROSTADIL
ALPROSTADIL 745-65-3
95% up, USP26
LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
GINKGO BILOBA EXTRACT
GINKGO BILOBA EXTRACT 90045-36-6
USP, EP, CP, 36/10=Flavone 36%+ Lactones 10%
Lenalidomide
Lenalidomide 191732-72-6
98% up, USP/BP
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact